US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Vyome Holdings, Inc.

2.24

+0.06002.75%

Volume:3K

Turnover:6.44K

Market Cap:15.72M

PE:-1.39

High:2.24

Open:2.23

Low:2.21

Close:2.18

52wk High:9.56

52wk Low:1.75

Shares:7.02M

Float Shares:1.54M

Volume Ratio:2.48

T/O Rate:0.19%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6111

EPS(LYR):-4.7480

ROE:-999.17%

ROA:-48.79%

PB:2.60

PE(LYR):-0.47

Loading ...

Overview Company News Filings

Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet

THOMSON REUTERS

Vyome - Q1 2026 Net Loss Attributable to Common Shareholders $963,000 or $0.15 per Share

THOMSON REUTERS

Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Vyome Holdings (HIND)

Vyome Holdings Q1 FY26 net loss widens to $985,521; revenue drops to $31,591

Vyome signs exclusive license agreement with Impetis

Vyome signs exclusive licensing deal with Impetis for selective JAK inhibitors

Vyome Holdings Inc - Receives Exclusive License for Selective Jak 1/3 and Jak1 Inhibitors

THOMSON REUTERS

Vyome Strikes Deal With Impetis Biosciences, Opening a ~$57B Market Opportunity

THOMSON REUTERS

Vyome initiated with a Buy at Litchfield Hills

Vyome Holdings shareholders approve cut in authorized common shares to 50 million

Vyome Holdings presents Phase 2 study results on VT-1953

Vyome presents Phase 2 data for VT-1953 in malignant fungating wounds at AACR

Vyome presents Phase 2 VT-1953 data for malignant fungating wounds at AACR 2026

Press Release: Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

Vyome Holdings Inc. Announces Annual Stockholders Meeting

Vyome Holdings FY 2025 net loss widened to USD 10.48 million as revenue rose 24.43% to USD 319,714

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/HIND/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HIND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIND\",,,,,undefined,":{"symbol":"HIND","market":"US","secType":"STK","nameCN":"Vyome Holdings, Inc.","latestPrice":2.24,"timestamp":1788448052376,"preClose":2.18,"halted":0,"volume":2890,"delay":0,"changeRate":0.027522935779816536,"floatShares":1543899,"shares":7018528,"eps":-1.611126,"marketStatus":"Trading","change":0.06,"latestTime":"09-03 11:12:50 EDT","open":2.23,"high":2.24,"low":2.2097,"amount":6441.959702,"amplitude":0.013899,"askPrice":2.3,"askSize":7,"bidPrice":2.2,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.611126,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788465600000},"marketStatusCode":2,"adr":0,"listingDate":1475726400000,"exchange":"NASDAQ","adjPreClose":2.18,"preHourTrading":{"tag":"盘前","latestPrice":2.22,"preClose":2.18,"latestTime":"09:29 EDT","volume":1268,"amount":2814.289862,"timestamp":1788442199057,"change":0.04,"changeRate":0.018349,"amplitude":0.006835},"postHourTrading":{"tag":"盘后","latestPrice":2.18,"preClose":2.18,"latestTime":"17:44 EDT","volume":53,"amount":113.2165,"timestamp":1788385440529,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.48382},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIND\",,,,,undefined,":{"symbol":"HIND","floatShares":1543899,"roa":"-48.79%","roe":"-999.17%","lyrEps":-4.747979,"volumeRatio":2.48382,"shares":7018528,"dividePrice":0,"high":2.24,"amplitude":0.013899,"preClose":2.18,"low":2.2097,"week52Low":1.75,"pbRate":"2.60","psRate":"121.19","week52High":9.56,"institutionHeld":0,"latestPrice":2.24,"committee":0.869159,"eps":-1.611126,"divideRate":0,"volume":2890,"delay":0,"ttmEps":-1.611126,"open":2.23,"prevYearClose":3.44,"prevWeekClose":2.205,"prevMonthClose":2.1602,"prevQuarterClose":2.15,"fiveDayClose":2.21,"twentyDayClose":2.14,"sixtyDayClose":2.11},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HIND\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"HIND","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.1},{"market":"US","date":"2026-06-03","symbol":"HIND","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1780459200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2026-05-12","symbol":"HIND","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2026-03-18","symbol":"HIND","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773806400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-14","symbol":"HIND","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":-3.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HIND\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HIND\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1777953600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HIND\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HIND","date":"2026-09-02","current":-1.353091,"percent":0.879845,"low":-23.816091,"twenty":-10.642365,"median":-1.552528,"eighty":-1.38047,"high":-0.001601,"avg":-5.317867,"sd":7.346072,"marketCap":15230205},"quantilePoints":[{"date":"2025-08-22","current":-12.854344,"twenty":-12.392244,"median":-11.699095,"eighty":-11.005946,"marketCap":20748595},{"date":"2025-08-29","current":-11.259279,"twenty":-13.22027,"median":-12.854344,"eighty":-11.500884,"marketCap":18173952},{"date":"2025-09-05","current":-9.124707,"twenty":-13.182739,"median":-11.259279,"eighty":-10.03366,"marketCap":14728473},{"date":"2025-09-12","current":-0.001997,"twenty":-12.854344,"median":-10.288753,"eighty":-0.00213,"marketCap":2910},{"date":"2025-09-19","current":-0.001751,"twenty":-12.467306,"median":-9.124707,"eighty":-0.001933,"marketCap":2551},{"date":"2025-09-26","current":-20.664803,"twenty":-13.499407,"median":-10.288753,"eighty":-0.001997,"marketCap":30109879},{"date":"2025-10-03","current":-20.473816,"twenty":-20.473816,"median":-11.259279,"eighty":-0.002098,"marketCap":29831599},{"date":"2025-10-10","current":-21.00858,"twenty":-21.00858,"median":-13.018541,"eighty":-0.002106,"marketCap":30610783},{"date":"2025-10-17","current":-19.327894,"twenty":-20.855791,"median":-13.499407,"eighty":-0.00213,"marketCap":28161920},{"date":"2025-10-24","current":-20.850495,"twenty":-20.850495,"median":-19.346992,"eighty":-0.002143,"marketCap":30380443},{"date":"2025-10-31","current":-21.039016,"twenty":-20.850495,"median":-19.786263,"eighty":-9.124707,"marketCap":30655130},{"date":"2025-11-07","current":-21.340651,"twenty":-21.039016,"median":-20.206435,"eighty":-10.010203,"marketCap":31094630},{"date":"2025-11-14","current":-18.588235,"twenty":-21.00858,"median":-20.168237,"eighty":-10.03366,"marketCap":27084192},{"date":"2025-11-21","current":-17.984966,"twenty":-21.00858,"median":-20.037322,"eighty":-10.543846,"marketCap":26205192},{"date":"2025-11-28","current":-3.129419,"twenty":-20.886349,"median":-19.767164,"eighty":-7.929274,"marketCap":29238478},{"date":"2025-12-05","current":-3.075047,"twenty":-20.851554,"median":-19.327894,"eighty":-3.104045,"marketCap":28730474},{"date":"2025-12-12","current":-2.881724,"twenty":-20.850495,"median":-18.663643,"eighty":-3.026716,"marketCap":26924236},{"date":"2025-12-19","current":-2.342231,"twenty":-20.820331,"median":-18.362009,"eighty":-2.975968,"marketCap":21883703},{"date":"2025-12-26","current":-2.271547,"twenty":-20.790168,"median":-17.381696,"eighty":-2.665444,"marketCap":21223297},{"date":"2026-01-02","current":-2.078224,"twenty":-20.744922,"median":-13.229653,"eighty":-2.363376,"marketCap":19417059},{"date":"2026-01-09","current":-2.072183,"twenty":-20.685727,"median":-12.660825,"eighty":-2.260673,"marketCap":19360614},{"date":"2026-01-16","current":-1.866777,"twenty":-20.618426,"median":-10.790143,"eighty":-2.104806,"marketCap":17441486},{"date":"2026-01-23","current":-1.761053,"twenty":-20.541319,"median":-10.03366,"eighty":-2.062517,"marketCap":16453700},{"date":"2026-01-30","current":-1.292849,"twenty":-20.511156,"median":-6.2932,"eighty":-1.940481,"marketCap":12079217},{"date":"2026-02-06","current":-1.38951,"twenty":-20.503688,"median":-3.129419,"eighty":-1.87886,"marketCap":12982336},{"date":"2026-02-13","current":-1.576792,"twenty":-20.469996,"median":-3.093171,"eighty":-1.729639,"marketCap":14732129},{"date":"2026-02-20","current":-1.661371,"twenty":-20.454717,"median":-3.029737,"eighty":-1.661371,"marketCap":15522358},{"date":"2026-02-27","current":-2.029893,"twenty":-20.435747,"median":-3.008592,"eighty":-1.661371,"marketCap":18965499},{"date":"2026-03-06","current":-1.758033,"twenty":-20.359224,"median":-2.95875,"eighty":-1.667412,"marketCap":16425477},{"date":"2026-03-13","current":-1.4318,"twenty":-20.28493,"median":-2.791104,"eighty":-1.619082,"marketCap":13377450},{"date":"2026-03-20","current":-1.254087,"twenty":-20.244632,"median":-2.425601,"eighty":-1.576792,"marketCap":12869446},{"date":"2026-03-27","current":-1.504653,"twenty":-20.168237,"median":-2.342231,"eighty":-1.56471,"marketCap":15440761},{"date":"2026-04-02","current":-1.470457,"twenty":-20.080611,"median":-2.271547,"eighty":-1.552627,"marketCap":15089835},{"date":"2026-04-10","current":-1.573046,"twenty":-20.054657,"median":-2.19603,"eighty":-1.544169,"marketCap":16142614},{"date":"2026-04-17","current":-1.518332,"twenty":-20.027528,"median":-2.096348,"eighty":-1.529274,"marketCap":15581132},{"date":"2026-04-24","current":-1.545689,"twenty":-19.83321,"median":-2.075203,"eighty":-1.529274,"marketCap":15861873},{"date":"2026-05-01","current":-1.388384,"twenty":-19.755705,"median":-2.0601,"eighty":-1.503285,"marketCap":14247611},{"date":"2026-05-08","current":-1.43626,"twenty":-19.442486,"median":-1.999686,"eighty":-1.470457,"marketCap":14738908},{"date":"2026-05-15","current":-1.232791,"twenty":-19.335533,"median":-1.945315,"eighty":-1.456778,"marketCap":13475573},{"date":"2026-05-22","current":-1.431836,"twenty":-19.175104,"median":-1.918128,"eighty":-1.435375,"marketCap":15651317},{"date":"2026-05-29","current":-1.508885,"twenty":-18.898194,"median":-1.893963,"eighty":-1.43449,"marketCap":16493540},{"date":"2026-06-05","current":-1.476781,"twenty":-18.648562,"median":-1.87886,"eighty":-1.43626,"marketCap":16142614},{"date":"2026-06-12","current":-1.46394,"twenty":-18.475122,"median":-1.845633,"eighty":-1.431822,"marketCap":16002243},{"date":"2026-06-18","current":-1.399732,"twenty":-18.384631,"median":-1.759543,"eighty":-1.421213,"marketCap":15300391},{"date":"2026-06-26","current":-1.354786,"twenty":-18.211192,"median":-1.721785,"eighty":-1.4023,"marketCap":14809094},{"date":"2026-07-02","current":-1.444678,"twenty":-17.864312,"median":-1.691578,"eighty":-1.395484,"marketCap":15791688},{"date":"2026-07-10","current":-1.431836,"twenty":-16.605238,"median":-1.658351,"eighty":-1.395484,"marketCap":15651317},{"date":"2026-07-17","current":-1.406153,"twenty":-13.445456,"median":-1.607243,"eighty":-1.397164,"marketCap":15370576},{"date":"2026-07-24","current":-1.374049,"twenty":-13.22027,"median":-1.588875,"eighty":-1.395224,"marketCap":15019649},{"date":"2026-07-31","current":-1.290579,"twenty":-13.182739,"median":-1.586725,"eighty":-1.393311,"marketCap":14107241},{"date":"2026-08-07","current":-1.374049,"twenty":-12.854344,"median":-1.573046,"eighty":-1.388384,"marketCap":15019649},{"date":"2026-08-14","current":-1.340677,"twenty":-12.467306,"median":-1.565459,"eighty":-1.38689,"marketCap":15160020},{"date":"2026-08-21","current":-1.415158,"twenty":-11.259279,"median":-1.558668,"eighty":-1.38689,"marketCap":16002243},{"date":"2026-08-28","current":-1.37171,"twenty":-10.790143,"median":-1.552627,"eighty":-1.38689,"marketCap":15510946},{"date":"2026-09-02","current":-1.346883,"twenty":-10.642365,"median":-1.552528,"eighty":-1.38047,"marketCap":15230205}],"updateTime":1788430146621},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HIND\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2638986286","title":"Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet","url":"https://stock-news.laohu8.com/highlight/detail?id=2638986286","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638986286?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969607,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA5JWQCX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4082","HIND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698401","title":"Vyome - Q1 2026 Net Loss Attributable to Common Shareholders $963,000 or $0.15 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698401","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698401?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969607,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA5JWQCX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","HIND","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636829826","title":"Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Vyome Holdings (HIND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636829826","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636829826?lang=en_us&edition=fundamental","pubTime":"2026-05-20 23:30","pubTimestamp":1779291009,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Medtronic (MDT) and Vyome Holdings (HIND) with bulli...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-medtronic-mdt-vyome-holdings-hind-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-medtronic-mdt-vyome-holdings-hind-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","LU0070302665.USD","LU0029874061.USD","IE00B3PB1722.GBP","IE00BVYPNV92.GBP","LU1983299246.USD","LU0265550946.USD","LU1116320737.USD","MDT","BK4533","LU2468319806.SGD","LU0976567544.SGD","BLSG","BK4007","IE00B3T34201.USD","LU0320765489.SGD","LU0006306889.USD","LU1244550577.SGD","XBI","LU0128526141.USD","LU1023059063.AUD","BK4137","LU2111349929.HKD","BK4581","LU0432979614.USD","LU2028103732.USD","LU0208291251.USD","BK4585","LU1244550221.USD","LU0158827948.USD","LU0162691827.USD","LU1291159041.SGD","LU1989764664.SGD","IE00BFXG1179.USD","LU2271345857.HKD","LU0314106906.USD","LU0211326755.USD","HIND","BK4112","IE00BQXX3D17.EUR","LU0072461881.USD","IE00BVYPNW00.USD","LU1057294990.SGD","LU0211326839.USD","LU0496365809.HKD","LU1116320901.HKD","LU1061106388.HKD","LU2112291526.USD","LU0122379950.USD","IE00BDGV0183.EUR","IE00BGHQF631.EUR","LU0158827781.USD","BK4082","LU1989771016.USD","IE00B42XCP33.USD","LABU","LU2089284900.SGD","BK4588","BLSX","LU0106261372.USD","LU1989764748.USD","LU0211331839.USD","LU1244550494.USD","LU1506573853.SGD","LU0265550359.USD","LU2089283258.USD","IE000M9KFDE8.USD","LU1571399168.USD","LU2023251221.USD","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635124209","title":"Vyome Holdings Q1 FY26 net loss widens to $985,521; revenue drops to $31,591","url":"https://stock-news.laohu8.com/highlight/detail?id=2635124209","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635124209?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:04","pubTimestamp":1778616259,"startTime":"0","endTime":"0","summary":"Vyome Holdings posted a net loss of $985,521 for the three months ended March 31, 2026, widening from $293,974 a year earlier.Revenue fell 84.09% to $31,591, while operating loss widened to $1.13 million from $198,998.Research and development expense climbed to $666,405 from $90,268, due to scaling up regulatory consulting and CMC preparation work for VT-1953.Selling, general and administrative expense rose to $477,575 from $259,626 on higher legal, accounting and auditing fees tied to the merger, with stock-based compensation of $5,696.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval syst","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL92XcSx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HIND","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635246500","title":"Vyome signs exclusive license agreement with Impetis","url":"https://stock-news.laohu8.com/highlight/detail?id=2635246500","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635246500?lang=en_us&edition=fundamental","pubTime":"2026-05-13 00:18","pubTimestamp":1778602702,"startTime":"0","endTime":"0","summary":"Vyome (HIND) Holdings announced the signing of an agreement with Impetis Biosciences, a TATA Enterprise, that gives it exclusive license to develop...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vyome-signs-exclusive-license-agreement-with-impetis-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vyome-signs-exclusive-license-agreement-with-impetis-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","HIND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634021622","title":"Vyome signs exclusive licensing deal with Impetis for selective JAK inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2634021622","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634021622?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:02","pubTimestamp":1778587342,"startTime":"0","endTime":"0","summary":"Vyome signed exclusive licensing agreement with Impetis Biosciences, TATA Enterprise, covering a selective JAK 1/3 inhibitor plus a selective JAK1 inhibitor for development and commercialization.Deal expands pipeline beyond lead program VT-1953, positioning company to enter broader immuno-inflammatory indications.JAK inhibitors market projected to reach USD 56.78 billion by 2030, up from USD 23.56 billion in 2025.Consideration structured to be tied to commercialization, with any future development planned through non-dilutive pathways.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire  on May 12, 2026, and is solely responsible for the in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL1dl0D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIND","BK4007","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216409","title":"Vyome Holdings Inc - Receives Exclusive License for Selective Jak 1/3 and Jak1 Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216409","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216409?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587247,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P0TI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HIND","BK4082","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216123","title":"Vyome Strikes Deal With Impetis Biosciences, Opening a ~$57B Market Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216123?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587247,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P0TI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HIND","BK4007","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632930760","title":"Vyome initiated with a Buy at Litchfield Hills","url":"https://stock-news.laohu8.com/highlight/detail?id=2632930760","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632930760?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:39","pubTimestamp":1777894774,"startTime":"0","endTime":"0","summary":"Litchfield Hills analyst Theodore O’Neill initiated coverage of Vyome (HIND) with a Buy rating and $8 price target The company’s drug development o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vyome-initiated-with-a-buy-at-litchfield-hills-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vyome-initiated-with-a-buy-at-litchfield-hills-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HIND","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631524806","title":"Vyome Holdings shareholders approve cut in authorized common shares to 50 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2631524806","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631524806?lang=en_us&edition=fundamental","pubTime":"2026-04-30 05:01","pubTimestamp":1777496509,"startTime":"0","endTime":"0","summary":"Vyome Holdings held its annual shareholder meeting on April 24, 2026.Stockholders adopted an amendment to certificate of incorporation cutting authorized common shares to 50,000,000 from 300,000,000.Company filed a tenth amendment to its certificate of incorporation on April 24, 2026, executing the authorized-share reduction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL6zfqlH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIND","BK4007","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629492860","title":"Vyome Holdings presents Phase 2 study results on VT-1953","url":"https://stock-news.laohu8.com/highlight/detail?id=2629492860","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629492860?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:37","pubTimestamp":1776861443,"startTime":"0","endTime":"0","summary":"Vyome Holdings (HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vyome-holdings-presents-phase-2-study-results-on-vt-1953-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vyome-holdings-presents-phase-2-study-results-on-vt-1953-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HIND","VT","BK4082","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629045062","title":"Vyome presents Phase 2 data for VT-1953 in malignant fungating wounds at AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2629045062","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629045062?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:03","pubTimestamp":1776859438,"startTime":"0","endTime":"0","summary":"Vyome presented full Phase 2 investigator-initiated study results for VT-1953 at AACR 2026 on April 21, 2026.VT-1953 showed clinically meaningful improvement in malignant fungating wound malodor versus vehicle control.Patient-reported quality of life improved on malodor impact measures, with pain also easing; exudate levels did not change.No treatment-associated adverse effects were reported in study.Vyome plans to advance VT-1953 into registrational studies, citing third-party estimates of USD 2.2 billion total addressable U.S. market for malignant fungating wound symptom treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire  on A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL6JV8Kk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","HIND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625545679","title":"Vyome presents Phase 2 VT-1953 data for malignant fungating wounds at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625545679","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625545679?lang=en_us&edition=fundamental","pubTime":"2026-04-06 20:00","pubTimestamp":1775476846,"startTime":"0","endTime":"0","summary":"Vyome set presentation of full Phase 2 results for VT-1953 topical gel in malignant fungating wounds at AACR Annual Meeting on April 21, 2026.Study readout showed VT-1953 outperformed vehicle in efficacy, with safety profile supporting advancement to pivotal studies.Management guided FDA interactions in Q2 2026 to align on pivotal trial design.Third-party analysts estimated total addressable US market at USD 2.2 billion.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL5mjnZ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","HIND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622852412","title":"Press Release: Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2622852412","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622852412?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:00","pubTimestamp":1774526400,"startTime":"0","endTime":"0","summary":"--  Completed a streamlined Nasdaq listing through a merger transaction,with a common stock capital structure and no preferred stock or debt. --  Delivered positive final Phase 2 results for VT-1953 in treating. symptoms of malignant fungating wounds, in line with expectations. --  Independent valuation consulting firm, Destum Partners, valued VT-1953. at approximately $1 billion after a successful pivotal study. --  Disciplined, cost-efficient operations as Vyome burned less cash than. expected, giving the company a cash runway expected to extend through mid. 2027, taking it up to pivotal trial interim readouts. The Company's lead clinical program, VT-1953, a novel, potential first-in-class topical product targeting symptoms of putrid smell and pain in malignant fungating wounds , which is an inflammatory condition afflicting an estimated one million cancer patients, continued to show strong clinical momentum.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIND","BK4007","VT","BK4585","BK4082","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621918754","title":"Vyome Holdings Inc. Announces Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2621918754","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621918754?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:57","pubTimestamp":1774040265,"startTime":"0","endTime":"0","summary":"Vyome will hold its annual meeting on April 15, 2026 in New York.Shareholders will vote to elect Venkat Nelabhotla and John Tincoff as Class II directors to serve until the 2029 annual meeting.An amendment to reduce authorized common shares to 50,000,000 from 300,000,000 will be submitted for approval.An advisory vote on named executive officer compensation is also scheduled.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL1yq4lG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIND","BK4082","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620232611","title":"Vyome Holdings FY 2025 net loss widened to USD 10.48 million as revenue rose 24.43% to USD 319,714","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232611","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232611?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:40","pubTimestamp":1773830411,"startTime":"0","endTime":"0","summary":"Vyome published its FY 2025 annual report on Form 10-K, reporting revenue of USD 319,714, up 24.43%. FY 2025 net loss widened to USD 10.48 million, while loss from operations was USD 10.45 million. Research and development expense rose more than doubled to USD 588,258 as the company resumed R&D after the merger with new funds raised. General and administrative expense increased more than doubled to USD 2.37 million, driven by higher professional fees tied to the merger and USD 577,128 in stock-based compensation. Vyome said it ended FY 2025 with cash of about USD 4.98 million and expects existing cash plus proceeds from the private placement and its ATM facility to fund operations for at least 15 months, including initiation of a pivotal trial for lead candidate VT-1953.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL7LttYd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIND","BK4082","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":36,"code":"91000000","status":"200"}]}}